EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Novel ALK immunohistochemistry assay (clone OTI1A4, Dako) is a sensitive, reliable marker for identifying ALK rearrangements in lung adenocarcinomas: A validation study

Ozgur Can Eren, Cisel Aydin Mericoz, Emine Bozkurtlar, Pinar Bulutay, Arzu Baygul, Ibrahim Kulac iD

American Journal of Clinical Pathology · 2024

DOI: 10.1093/ajcp/aqad111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Ozgur Can Eren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Koç University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ventana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We present the first study validating the recent Dako ALK assay (clone OTI1A4, in vitro diagnostic) for detecting ALK rearrangements in lung adenocarcinoma.

Methods

Lung adenocarcinoma cases between 2011 and 2023 were retrospectively collected to create a cohort of 203 samples. Cases were stained with Dako ALK OTI1A4 and Ventana ALK D5F3 and reviewed by 3 pathologists independently. Correlation between assays, including their sensitivity and specificity, was evaluated.

Results

The cohort (n = 203) consisted of resections, core needle biopsies, and cell blocks. Agreement between Dako ALK OTI1A4 and Ventana ALK D5F3 assays was “almost perfect,” with κ = 0.89. The sensitivity and specificity of the Dako ALK OTI1A4 assay were 93.3% and 96%, respectively, in a subgroup of 55 molecularly confirmed cases (n = 30 with and n = 25 without ALK rearrangement).

Conclusions

Immunohistochemistry-based assays provide a valid and reasonably priced alternative, especially in settings where molecular confirmatory tests are neither offered nor accessible. Given high interassay and molecular concordance, we propose that the novel Dako OTI1A4 assay can be reliably used to identify cases with ALK rearrangement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungHumansReceptor Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseRetrospective StudiesImmunohistochemistryIn Situ Hybridization, FluorescenceGene Rearrangement

Stichwörter der Autor:innen

ALK D5F3ALK OTI1A4immunohistochemistrylung adenocarcinomapredictive testingvalidation

Substanzen

Receptor Protein-Tyrosine KinasesAnaplastic Lymphoma Kinase

Autor:innen und Institutionen

  • Department of Pathology, Koç University School of Medicine, Istanbul, Turkey.
  • Department of Immunology, Graduate School of Health Sciences, Koç University, Istanbul, Turkey.
  • Koç University IsBank Research Center for Infectious Diseases, Istanbul, Turkey.
  • Department of Pathology, Marmara University School of Medicine, Istanbul, Turkey.
  • Department of Biostatistics, Koç University School of Medicine, Istanbul, Turkey.
  • Research Center for Translational Medicine, Koç University, Istanbul, Turkey.

ORCID-Profile: Ibrahim Kulac

Förderung

  • Ventana

Zitieren

APA

Eren, O. C., Mericoz, C. A., Bozkurtlar, E., Bulutay, P., Baygul, A., & Kulac, I. (2024). Novel ALK immunohistochemistry assay (clone OTI1A4, Dako) is a sensitive, reliable marker for identifying ALK rearrangements in lung adenocarcinomas: A validation study. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad111

Vancouver

Eren OC, Mericoz CA, Bozkurtlar E, Bulutay P, Baygul A, Kulac I. Novel ALK immunohistochemistry assay (clone OTI1A4, Dako) is a sensitive, reliable marker for identifying ALK rearrangements in lung adenocarcinomas: A validation study. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad111

BibTeX
@article{Eren2024,
  author = {Eren, Ozgur Can and Mericoz, Cisel Aydin and Bozkurtlar, Emine and Bulutay, Pinar and Baygul, Arzu and Kulac, Ibrahim},
  title = {Novel ALK immunohistochemistry assay (clone OTI1A4, Dako) is a sensitive, reliable marker for identifying ALK rearrangements in lung adenocarcinomas: A validation study},
  journal = {American Journal of Clinical Pathology},
  year = {2024},
  doi = {10.1093/ajcp/aqad111}
}
Kostenlos starten →